Oral Diabetes Drug Cuts Heart Risks by 14% in Trial

 ‌

Breaking News from Newsmax Health

An oral version of the injected drug semaglutide (Ozempic, Wegovy) helped significantly reduce the risk of cardiovascular events in patients in a late-stage study, according to Novo Nordisk. The oral formulation (Rybelsus) helped reduce the odds of cardiovascular death, non-fatal heart attack, and stroke by 14% compared to placebo. Read More Here Special: This 'Healthy' Breakfast Wrecks Your Blood Sugar SPONSOR   ADVERTORIAL Modern food manufacturing has set a metabolic trap that forces your insulin to spike 41% higher …and stay sky-high for HOURS — NOT GOOD! But today, a new discovery promises an effortless way to support healthy blood sugar, while also helping you stay slim and healthy, all year round. This discovery helps preserve steady, all-day energy…effortless fat loss…and the overall metabolic health you cherished in your younger days. Metabolic distress is rampant in America. Making matters worse, the damage some "health foods" have on my patients' blood sugar is devastating, making weight management a real issue. Just CLICK HERE, and I'll explain everything in my special report. To Your Good Health, Al Sears, MD, CNS *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.   To Read More Health News go to NewsmaxHealth.com This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below. TO ADVERTISE For information on advertising, please contact Newsmax Advertising Sales via email. TO SUBSCRIBE If this email has been forwarded to you and you would like to sign up, please click here. Remove your email address from our list or modify your profile. We respect your right to privacy. View our policy. This email was sent by: Newsmax.com 362 N. Haverhill Road West Palm Beach, FL 33415 USA DM703638 010502izj7vc